Xena Bioherbals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 31-07-2024
- Paid Up Capital ₹ 0.20 M
as on 31-07-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 M
as on 31-07-2024
- Revenue -95.22%
(FY 2023)
- Profit -523.00%
(FY 2023)
- Ebitda -143.86%
(FY 2023)
- Net Worth -57.10%
(FY 2023)
- Total Assets -50.41%
(FY 2023)
About Xena Bioherbals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.50 M.
Prem Pushpala and Beena Pushpala serve as directors at the Company.
- CIN/LLPIN
U74999TG2007PTC052288
- Company No.
052288
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Xena Bioherbals Private Limited offer?
Xena Bioherbals Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Fruit Extracts, Nutraceuticals & Dietary Supplements, Dietary Supplements, Herbal Extracts, Nutritional Supplements, Seeds and Plant Saplings, Tree Seeds, Common Disease Medicines, Pharmaceutical Capsules.
Who are the key members and board of directors at Xena Bioherbals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Pushpala  | Director | 23-Feb-2009 | Current |
| Beena Pushpala | Director | 01-Dec-2010 | Current |
Financial Performance and Corporate Structure Insights of Xena Bioherbals.
Xena Bioherbals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.22% decrease. The company also saw a substantial fall in profitability, with a 523% decrease in profit. The company's net worth observed a substantial decline by a decrease of 57.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xena Bioherbals?
In 2023, Xena Bioherbals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 20 Jan 2016 | ₹1.50 M | Open |
How Many Employees Work at Xena Bioherbals?
Unlock and access historical data on people associated with Xena Bioherbals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xena Bioherbals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xena Bioherbals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
